Table 4. Summary of clinical trials examining dual blockade of BRAF and EGFR in BRAF-positive metastatic colorectal cancer*.

Study	Description	Primary endpoint
SWOG S1406 (NCT02164916)	Phase II RCT comparing combination cetuximab and irinotecan with and without vemurafenib	PFS
LGX818, cetuximab, BYL719 (NCT01719380)	Phase Ib/II open-label, dose escalation study of LGX818 with cetuximab or LGX818 with cetuximab and BYL719	Incidence rate of DLT, PFS
BRAF/MEK/EGFR inhibitor combination (NCT01750918)	Phase Ib/II open-label, dose escalation study of trametinib/dabrafenib with panitumumab versus FOLFOX	Adverse events, RR, PFS
Vemurafenib and panitumumab combination therapy (NCT01791309)	Pilot study of combination vemurafenib and panitumumab	ORR
WNT974 in combination with LGX818 and cetuximab (NCT02278133)	Phase Ib/II open-label, dose escalation study of triple combination WNT974, LGX818, and cetuximab	Incidence rate of DLT, ORR

*, accessed from www.clinicaltrials.gov on June 7, 2016. EGFR, epidermal growth factor receptor; SWOG, Southwestern Oncology Group; RCT, randomized controlled trial; PFS, progression free survival; DLT, dose limiting toxicity; RR, response rate; ORR, objective response rate.